Drugs / KL340399
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05549804 | Aug 2022 → Apr 2025 | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05387928 | Jun 2022 → Apr 2025 | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KL340399 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05387928 ↗ |
| Action | Activate | “KL340399 injection is a STING-activating.” NCT05387928 ↗ |